Apoorv Shanker

This paper develops a nanoparticle platform to target TLR3 agonist to antigen-presenting cells, improving cancer immunotherapy safety and efficacy by reducing systemic toxicity and enhancing tumor targeting.

This paper introduces a structure-based workflow to optimize signal peptides for enhanced antigen expression in human cells, showing that structurally optimized SPs improve protein secretion for vaccine candidates.

SignalGen predicts optimal signal peptides for protein expression by integrating mature protein sequences, organism, and localization using a Latent Residual Transformer.

This study develops IL-12-loaded nanoparticles that enhance immunotherapy for metastatic ovarian cancer by promoting T cell accumulation and sensitizing tumors to checkpoint inhibitors.

The paper introduces metrics to quantify CD8+ T cell responses to vaccine antigens, considering HLA genetic variation and viral evolution, using Ebola, SARS-CoV-2, and Burkholderia pseudomallei as examples.